Tuesday, September 24, 2019
- 1:45pm-3:15pm
-
Unusual expression of fragile X premutation in a female patient: clinical and tractographic description
Dystonia · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Use of Chemodenervation for Secondary Limb Dystonia in Parkinson’s Disease: A Single Center Experience
Dystonia · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Using Quantitative Susceptibility Mapping to Predict Dementia in Parkinson’s Disease
Parkinsonisms and Parkinson-Plus · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Utilising Magnetic Resonance Spectroscopy to investigate synucleinopathies
Parkinsonisms and Parkinson-Plus · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Utility of Eye Movement Abnormalities in Differentiating Neurodegenerative versus non-Neurodegenerative Parkinsonism
Parkinsonisms and Parkinson-Plus · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Validation of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease
Rating Scales · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Validation of the diagnostic criteria for progressive supranuclear palsy in pathologically confirmed patients
Parkinsonisms and Parkinson-Plus · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Validation of the Hebrew version of the Unified Dyskinesia Rating Scale (UDysRS)
Rating Scales · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Validation of the Movement Disorder Society criteria for the diagnosis of 4R-tauopathies
Parkinsonisms and Parkinson-Plus · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Validation of the PREDIGT Score for the Incidence Rate of Parkinson disease
Parkinsonisms and Parkinson-Plus · Agora 3 West, Level 3